logo
Northern Trust在香港新增投資資料科學客戶

Northern Trust在香港新增投資資料科學客戶

Business Wire4 days ago

香港--(BUSINESS WIRE)--(美國商業資訊)-- Northern Trust (Nasdaq: NTRS)今天宣布,該公司已被香港資產管理公司Clean Alpha Partners和Keyrock Capital Management Limited選中,透過與Equity Data Science (EDS)的策略夥伴關係提供投資資料科學解決方案。
成立於2024年的Clean Alpha Partners (「Clean Alpha」)是一家市場中性對沖基金,旨在從全球能源轉型中獲取高夏普比率的回報。Keyrock Capital Management Limited (「Keyrock」)成立於2018年,是一家專注於亞太地區企業的基本面投資公司。
根據新的委託,Northern Trust將提供對EDS研究管理系統(RMS)的使用權。該工作流程解決方案整合了即時的量化與質化資料,透過可行的洞察,推動更快速、更具資訊依據的投資決策。
「對沖基金經理所採用的複雜且精密的策略,需要對市場動態、情緒與風險有深入的理解,」 Northern Trust資產服務部亞太區主管Angelo Calvitto表示。 「EDS研究管理平台的設計,是為了協助投資團隊更輕鬆地分析有助於決策的資料。我們獲得Keyrock和Clean Alpha的選用,展現了Northern Trust致力於為亞太區資產管理公司提供針對其獨特挑戰的解決方案。」
「在Keyrock,我們意識到分析師產出大量資料,但我們需要一種方式來追蹤預測,並將其整合進研究報告與投資論文中,」 Keyrock首席投資長Jonathan Shih表示。 「我們尋求一個合作夥伴來協助我們彌補這項缺口,最終選擇了Northern Trust和EDS。我們現在可以將資料整合至同一平台中,支援我們的內部流程,並提升研究管理的效率。」
「資料在我們的決策過程中扮演關鍵角色,我們需要一個足夠彈性的解決方案,以支援我們量身打造的方法論,並更有效地管理專有資訊,」 Clean Alpha Partners創辦人暨首席投資長Matt Starick 表示。「Northern Trust和EDS所提供的解決方案,讓我們得以透過集中式平台來組織資料,進而提高投資決策的效率。」
Northern Trust的 投資資料科學 (IDS) 產品組合在過去兩年中實現了快速增長,客戶數量已經成長三倍,因為機構投資者積極尋求解決資料挑戰的方案。這一業務動能證明了Northern Trust及其策略夥伴所提供獨特解決方案的價值,能夠協助客戶最佳化投資流程,以實現更佳成果。
Northern Trust在亞太地區於北京、班加羅爾、香港、吉隆坡、馬尼拉、墨爾本、浦那、新加坡、雪梨及東京均設有辦事處,並與該地區內多家大型資產管理公司、中央銀行、主權財富基金、政府機構與企業建立了穩固的合作關係。
關於Equity Data Science
Equity Data Science (EDS)是一家投資流程管理(IPM)解決方案提供商,自2012年以來深受信賴,致力於為領先的對沖基金與資產管理公司提供更深入的洞察、精簡的工作流程與提升的生產力,以實現更卓越的決策。EDS結合專有與第三方的數據與研究,打造出靈活且可配置的平台,量身定制以符合每位客戶獨特的投資願景。此一全面性的平臺涵蓋整個投資生命週期,包含投資構想產生、研究管理、投資組合建構與分析、風險管理、績效歸因,以及ESG整合。如需更多資訊,請造訪 www.equitydatascience.com 。
關於Keyrock Capital Management Limited
Keyrock Capital Management Limited(「Keyrock」)總部設於香港,並在東京及胡志明市設有辦事處。由於亞洲地區的複雜性與快速變化,進入亞洲市場充滿挑戰。憑藉當地資源,Keyrock能夠發掘並投資於亞太地區被低估的公司。投資組合公司經過對管理團隊、商業模式、競爭情況及結構性趨勢的審慎研究後方才遴選。資本將配置於整個地區,以尋求最佳的風險與回報機會。該公司成立於2018年,並受香港證券及期貨事務監察委員會監管。
關於Clean Alpha Partners
Clean Alpha Partners(「CαP」)是一家投資管理公司,在澳洲、香港及美國設有辦公室。CαP的使命是從全球能源轉型中提取並複利累積股票市場的超額報酬(Alpha)。該策略旨在於各種市場情況下實現回報最大化、系統性風險最小化,以及提供高夏普比率的績效表現。此策略採用嚴格的股票市場中性投資組合建構方式。
關於Northern Trust
Northern Trust Corporation (Nasdaq: NTRS)是全球領先的財富管理、資產服務、資產管理及銀行服務提供者,服務對象包括企業、機構、富裕家族與個人。Northern Trust於1889年創立於芝加哥,目前在美國24個州及華盛頓特區設有辦公室,並在加拿大、歐洲、中東及亞太地區共22個地點設有據點,擁有全球業務布局。截至2025年3月31日,Northern Trust的託管/管理資產總額為16.9兆美元,管理資產達1.6兆美元。135年來,Northern Trust憑藉卓越的服務、金融專業、誠信與創新,在業界中樹立了領導地位。歡迎造訪我們的網站 northerntrust.com 。追蹤我們的 Instagram @northerntrustcompany或在 LinkedIn 上關注Northern Trust。
Northern Trust Corporation,總公司地址:50 South La Salle Street, Chicago, Illinois, U.S.A.,郵遞區號60603,為在美國依法註冊成立之有限責任公司。全球法律與監管相關資訊請參閱: https://www.northerntrust.com/terms-and-conditions 。
免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

Business Wire

timean hour ago

  • Business Wire

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

Upcoming Stock Splits This Week (June 30 to July 4)
Upcoming Stock Splits This Week (June 30 to July 4)

Business Insider

timean hour ago

  • Business Insider

Upcoming Stock Splits This Week (June 30 to July 4)

These are the upcoming stock splits for the week of June 30 to July 4, based on TipRanks' Stock Splits Calendar. In simple terms, a stock split boosts the number of outstanding shares by issuing more to current shareholders, while keeping the company's overall market value intact. This maneuver lowers the share price, often making the stock more affordable, and therefore more appealing, to everyday investors. Don't Miss TipRanks' Half Year Sale Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. On the flip side, some companies choose a reverse stock split, merging shares rather than dividing them. This trims the total share count while raising the price per share, again without changing the company's total market worth. Reverse splits are frequently used to meet minimum price requirements on exchanges like the Nasdaq and help avoid delisting. Whether aiming to attract more investors or stay in good standing with exchanges, these corporate moves can send important signals that investors watch closely. Let's take a look at the upcoming stock splits for the week. Ainos (AIMD) – Ainos is a dual-platform AI and biotech company, developing the 'AI Nose' scent digitization platform alongside oral interferon therapeutics for rare and autoimmune diseases. On June 26, Ainos announced a 1‑for‑5 reverse stock split, aiming to lift its share price above Nasdaq's minimum. The split will take effect at market open on June 30. Helius Medical Technologies (HSDT) – Helius Medical Technologies, known for its innovative neuromodulation devices like the PoNS® platform for neurological recovery, announced a 1-for-50 reverse stock split on June 27 to maintain compliance with Nasdaq listing requirements. The split will take effect on June 30, with Helius shares set to trade on a split-adjusted basis starting July 1. APi Group (APG) – APi Group specializes in safety, specialty, and industrial services. On May 21, APG announced a 3‑for‑2 forward stock split, conceived to lower per‑share price, increase retail access, and improve liquidity. The ex‑date is July 1, with adjusted trading beginning that day. Channel Therapeutics (CHRO) – Channel Therapeutics is a pain‑treatment biotech preparing for a merger with Pelthos Therapeutics and a NYSE American uplist. On June 27, the company announced a 10‑for‑1 reverse split to comply with listing standards and support a $50 million private placement. The split is effective before market open July 1, with split‑adjusted trading under 'Pelthos Therapeutics' starting July 2. SciSparc (SPRC) – Tel Aviv–based SciSparc, a clinical-stage developer of central nervous system therapies, announced on June 24 a 1-for-21 reverse share split to raise its share price and maintain compliance with Nasdaq listing standards. The split will take effect at market open on July 3. TipRanks Stock Splits Calendar.

Which "Magnificent Seven" Stock Makes the Best Buy for the Second Half?
Which "Magnificent Seven" Stock Makes the Best Buy for the Second Half?

Yahoo

timean hour ago

  • Yahoo

Which "Magnificent Seven" Stock Makes the Best Buy for the Second Half?

Tech stocks known as the "Magnificent Seven" led market gains last year. One particular AI leader rose 800% over three years but still has plenty of room to run. 10 stocks we like better than Nvidia › A group of technology stocks, known as the "Magnificent Seven" -- a nod to the 1960 Western -- led stock market gains last year and has started to rebound in recent times. Which one makes the best buy for the second half? The answer to that question is Nvidia (NASDAQ: NVDA), even though the stock has already climbed 800% over the past three years. Let's find out why this top artificial intelligence (AI) stock may still be in the early days of its growth story. Nvidia has played a key role since the first days of the AI boom, and this is because it designs the crucial element that makes AI work: chips. They're known as graphics processing units (GPUs), and they power the fundamental step of training AI models, a process that allows those models to then handle complex tasks and solve real-world problems. So, without these chips, we wouldn't have AI. This helped Nvidia's revenue take off a few years ago, as you can see in the chart below. In Nvidia's earlier days, it primarily served the video gaming market, which resulted in progressive growth, but revenue levels were a far cry from today's AI-driven revenue. This is because companies realize the potential of this technology to save them time and money and even help them develop game-changing products and services, so they're pouring investment into AI. And Nvidia, as the leading chip designer, is benefiting. This potential is further illustrated by forecasts calling for the AI market to reach into the trillions of dollars in a few years from now. Importantly, Nvidia isn't just about GPUs. The company has built an AI empire, creating software and networking tools, and it even aims to power the humanoid robots of tomorrow. This expansion is key to Nvidia's growth because it enables the company to benefit from every stage of AI development -- not just the early days of infrastructure ramp-up. Meanwhile, Nvidia has also put the focus on innovation to ensure it stays ahead of its rivals. It has pledged to update its chips yearly and has already offered investors visibility into planned launches over the coming three years. Though rivals are carving out market share -- for example, Advanced Micro Devices recently reported a 57% increase in data center quarterly revenue -- Nvidia's innovation should keep it in the top spot. The enormous demand for AI means that others, like AMD, can succeed without truly encroaching on Nvidia's territory. The biggest disappointment for Nvidia and investors at this point (and possibly into the future) is the situation concerning exports to China. The U.S. has blocked chip exports, cutting Nvidia out of the market that represented 13% of its revenue last year. This isn't a non-event, and if the situation remains as is, it limits Nvidia's growth opportunities to some degree. The good news is that Nvidia makes most of its revenue in the U.S. and a great deal in other locations as well, so the export situation doesn't necessarily translate to slow growth for this chip giant. All this sounds positive, but why is Nvidia the best Magnificent Seven buy for the second half? Nvidia remains the best overall AI bet due to its deep presence across every stage of the technology's growth. The world's biggest tech companies turn to Nvidia to power their platforms, and that's unlikely to change, as these customers aim to use the fastest processors available -- and those are likely to have the name Nvidia on them well into the future. Nvidia will accompany these customers as they deploy AI agents within their businesses or develop humanoid robots down the road. At the same time, Nvidia's valuation leaves the stock plenty of room to run. Though it's inched higher in recent weeks, it still trades significantly lower than it did just a few months ago, at 36 times forward earnings estimates compared to more than 50 times. All these elements, from Nvidia's presence across AI to its price today, support my prediction that this stock will roar higher in the second half and over the long run, too. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices and Nvidia. The Motley Fool has a disclosure policy. Which "Magnificent Seven" Stock Makes the Best Buy for the Second Half? was originally published by The Motley Fool Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store